New Discovery Reduces Chronic Inflammation — Will It Help MC Patients?

By Wayne Persky

RSS Feed

A study from the University of Bonn, claimed to be groundbreaking, has identified a powerful new compound that may offer relief for patients suffering from hard-to-treat allergic and inflammatory conditions, including irritable bowel syndrome (IBS), asthma, chronic pruritus, and potentially microscopic colitis (MC) and other IBDs.​

The compound, named PSB-172656, works by blocking a little-known immune receptor called MRGPRX2, which is found on mast cells. Mast cells are heavily involved in inflammatory reactions, especially those that occur without IgE antibodies,such as drug-induced allergies, neuroinflammation, or non-IgE mediated hypersensitivity. The research was published in Signal Transduction and Targeted Therapy and widely reported by Medical Xpress on April 24, 2025 (Al Hamwi, et al., 2025; Seiler, 2025, April 24).1, 2

Note that the receptor MRGPRX2 is primarily involved in non-IgE mediated mast cell activation. It does not directly bind IgA, and IgA immune complexes are not known to activate mast cells through MRGPRX2. Instead, MRGPRX2 is activated by other signals such as:

• Certain peptides (for example, substance P, vasoactive intestinal peptide)
• ​Some drugs (for example, fluoroquinolone antibiotics, neuromuscular blockers)
• Host defense peptides, such as LL-37
• Environmental irritants
• Some small-molecule allergens

In other words, MRGPRX2 is part of a non-antibody, direct activation system, distinct from classic antibody-driven responses.

How does this compare with normal IgE and IgA reaction pathways?

IgE Pathway:
IgE antibodies bind to FcεRI receptors on mast cells. When allergens cross-link these IgE molecules, mast cells rapidly release histamine and other inflammatory mediators, causing classic allergic reactions like hives or anaphylaxis.

MRGPRX2 Pathway:
Certain peptides, medications, and irritants directly activate MRGPRX2 receptors on mast cells without needing antibodies. This causes rapid mast cell degranulation and inflammation, often seen in drug reactions and chronic inflammation.

IgA Pathway:
IgA antibodies mainly interact with FcαRI (CD89) receptors on immune cells (such as macrophages and neutrophils, rarely mast cells directly). In special cases, IgA immune complexes can trigger inflammation indirectly, but mast cell activation through IgA is much less common and not through MRGPRX2.​

Therefore, mast cells can be activated through IgE for classic allergies, through MRGPRX2 for direct non-antibody triggers, and only rarely and indirectly through IgA immune complexes—each pathway driving inflammation in different ways.

Here's why MRGPRX2 matters.

MRGPRX2 is a mast cell receptor involved in non-traditional allergic responses and chronic inflammatory signaling. Unlike classic IgE-mediated allergic reactions (like hay fever or food allergies), MRGPRX2 triggers localized or systemic inflammation in response to certain medications, neuropeptides, and environmental stimuli.

This receptor is implicated in a variety of painful and difficult-to-treat conditions, including:
​

• Chronic itching and urticaria
• Drug-induced pseudo-allergic reactions
• Neurogenic inflammation
• IBS and possibly other GI conditions such as MC

The University of Bonn researchers found that PSB-172656 is capable of binding to and inhibiting MRGPRX2 with extremely small (subnanomolar) potency, preventing mast cell degranulation and the release of inflammatory mediators.

The compound stopped anaphylactic reactions in mice and reduced local inflammation in tracheal and skin models. It was shown to be highly selective for MRGPRX2 and its mouse counterpart MRGPRB2. The effect was replicated in human skin mast cells and mast cell lines, confirming its potential relevance in human disease. The molecule was engineered for metabolic stability, low toxicity, and prolonged action, making it a strong candidate for drug development.

Why might this matter for MC patients?

Although the study did not specifically test PSB-172656 regarding MC, the mechanism of action and targeted pathway suggest strong potential relevance:​

1. Research shows mast cells are active in microscopic colitis, contributing to mucosal inflammation, intestinal permeability, and symptom severity. MRGPRX2-mediated activation could be one of the unexplored contributors to persistent inflammation in MC.
2. Many IBD and MC patients suffer from reactions not mediated by classic allergies. Blocking MRGPRX2 could suppress this non-IgE mediated immune activation, potentially easing symptoms.
3. MC often overlaps with IBS-like symptoms (bloating, urgency, pain), and may be exacerbated by mast cell activity. This new compound may offer relief by modulating hypersensitive gut responses.
4. MC patients may be especially sensitive to certain antibiotics, NSAIDs, or SSRIs, some of which may activate mast cells via MRGPRX2. Blocking this pathway could reduce adverse reactions.​

Will this discovery resolve MC cases that are refractive to treatment?

For MC patients, many of whom struggle with ongoing symptoms despite dietary changes and medical treatments using corticosteroids, this novel MRGPRX2 blocker might one day offer a targeted, non-steroidal alternative. As understanding of mast cell-related gut inflammation grows, therapies like PSB-172656 may finally bring relief to those whose condition defies conventional treatment.

References

1. Al Hamwi, G., Alnouri, M.W., Verdonck, S., Leonczak, P., Chaki, S., Frischbutter, S., . . . Müller, C. E. (2025). Subnanomolar MAS-related G protein-coupled receptor-X2/B2 antagonists with efficacy in human mast cells and disease models. Signal Transduction Targeted Therapy, (10)128. Retrieved from https://www.nature.com/articles/s41392-025-02209-8

2. Seiler, J. (2025, April 24), Bioactive compound blocks key immune receptor to ease hard-to-treat allergic reactions. Medical Xpress, Retrieved from https://medicalxpress.com/news/2025-04-bioactive-compound-blocks-key-immune.html